KLRS
NASDAQKalaris Therapeutics Inc.
Price$3.76-0.16 (-4.08%)
01:30 PM07:45 PM
News · 26 weeks49-27%
2026-01-252026-07-19
Mix2590d
- Insider10(40%)
- SEC Filings6(24%)
- Other5(20%)
- Analyst2(8%)
- Leadership2(8%)
Latest news
25 items- INSIDERSEC Form 4 filed by Chief Financial Officer Bayko Liisa Ann4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bayko Liisa Ann3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- SECSEC Form 8-K filed by Kalaris Therapeutics Inc.8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- PRKalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial OfficerStrategic finance leader with over 20+ years of experience in the biotechnology space CFO hire bolsters Kalaris’ leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study of TH103 in treatment naïve nAMD patients BERKELEY HEIGHTS, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Liisa Bayko, MBA, as Chief Financial Officer. "I am delighted to welcome Liisa to our team," said Andrew Oxtoby, President and Chief Executive Officer of Kal
- SECKalaris Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- PRKalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD CohortsData from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts Enrollment in the Phase 1b/2 multiple-ascending dose trial of TH103 continues, with preliminary data on track for 1H 2027 BERKELEY HEIGHTS, N.J., July 17, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced positive additional data from its Phase 1a single ascending dose (SAD) trial of TH103 in neovascular age-related macular degeneration (AMD). Data from the expa
- SECSEC Form 8-K filed by Kalaris Therapeutics Inc.8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- PRKalaris Appoints Laurie Keating to Board of DirectorsBERKELEY HEIGHTS, N.J., July 06, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. In conjunction with the announcement of Ms. Keating’s appointment, Morana Jovan-Embiricos is stepping down from the Board of Directors. "We’re delighted to welcome Laurie to the Kalaris Board of Directors. She has extensive strategic, operational, and legal expertise spanning multiple therapeutic areas and development stages. Laurie will be
- PRKalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively EnrollingBERKELEY HEIGHTS, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced an upcoming presentation of Phase 1a data at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. ASRS Presentation Details: Title: First-in-Human Evaluation of TH103, a Novel Dual-Targeting VEGF/HSPG Biologic: Phase 1 Single Ascending Dose Study in Treatment-Naïve Neovascular AMDSpeaker: Joel Pearlman, MD, PhD, Retinal Consultants Medical GroupDate: Friday, July 17, 2026Time: 8:00 am EDTSession: AMD - Neov
- ANALYSTTD Cowen initiated coverage on Kalaris TherapeuticsTD Cowen initiated coverage of Kalaris Therapeutics with a rating of Buy
- PRKalaris to Present at Clinical Trials at the Summit 2026BERKELEY HEIGHTS, N.J., June 12, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, will present Phase 1a clinical data for its lead asset, TH103, at Clinical Trials at the Summit (CTS) 2026. The presentation will feature single ascending dose results from treatment-naïve patients with Neovascular Age-Related Macular Degeneration (AMD) — one of the leading causes of vision loss worldwide. These data were recently presented at Retina World Congress 2026. Details: Title: First-in-Human Trial of TH103: A Novel Dual-Targeting
- INSIDERSEC Form 4 filed by Director Jovan-Embiricos Morana4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 4 filed by Director Ferrara Napoleone4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 4 filed by Director Hallal David4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 4 filed by Director Akkaraju Srinivas4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 4 filed by Director Dybbs Michael4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 4 filed by Director Adamis Anthony P4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 4 filed by Director Patterson Leone D4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- SECSEC Form 8-K filed by Kalaris Therapeutics Inc.8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Kalaris Therapeutics Inc.SCHEDULE 13D/A - Kalaris Therapeutics, Inc. (0001754068) (Subject)
- INSIDERDirector Akkaraju Srinivas bought $1,179,969 worth of shares (244,300 units at $4.83), disposed of 66,906 shares and acquired 19,408 shares (SEC Form 4)4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- ANALYSTWedbush initiated coverage on Kalaris Therapeutics with a new price targetWedbush initiated coverage of Kalaris Therapeutics with a rating of Outperform and set a new price target of $17.00
- SECSEC Form 10-Q filed by Kalaris Therapeutics Inc.10-Q - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form 8-K filed by Kalaris Therapeutics Inc.8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- PRKalaris Reports First Quarter 2026 Financial Results and Provides Business UpdatesPatient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; preliminary data anticipated in 1H 2027 Planned Phase 3 clinical trials remain on track for 2027 year-end initiation $104.9 million in cash, cash equivalents and marketable securities as of March 31, 2026 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseas
KLRS FAQ
6 questionsWhere does KLRS stock trade?
Kalaris Therapeutics Inc. (KLRS) is listed on NASDAQ.What sector and industry is KLRS in?
Kalaris Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Kalaris Therapeutics Inc. go public?
Kalaris Therapeutics Inc. (KLRS) completed its IPO in 2020.What are analysts saying about KLRS?
Kalaris Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2026-06-15.What companies are similar to KLRS?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare KLRS side-by-side with any of them on Quantisnow.How can I track KLRS on Quantisnow?
Quantisnow aggregates Kalaris Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KLRS to receive live email and push alerts on every new disclosure.